Treatment of Advanced Solid Tumors
common.study.values.description
“An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors”
The purpose of the dose escalation part of this study is to determine the feasibility of using the combination of copanlisib and nivolumab in subjects with advanced solid tumors, and to determine the maximum tolerated dose of copanlisib in combination with nivolumab. The maximum tolerated dose will then be used in Phase 2 (dose expansion) of the study.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Copanlisib
Copanlisib: lyophilisate for reconstitution and further dilution for infusion
Drug - Nivolumab
Nivolumab: concentrate for solution for infusion
participant.views.study.view.additional
participant.views.study.view.scientific-title
An Open-label, Multi-center, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors.
common.study.values.clinical-trial-id
NCT03735628
participant.views.study.view.id
dwpEwe
